Gilder Gagnon Howe & Co. LLC Grows Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 88.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 37,144 shares of the biopharmaceutical company's stock after purchasing an additional 17,437 shares during the period. Gilder Gagnon Howe & Co. LLC's holdings in Gilead Sciences were worth $3,431,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. FMR LLC lifted its stake in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after acquiring an additional 7,157,113 shares during the period. Wellington Management Group LLP lifted its stake in Gilead Sciences by 3.1% during the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after acquiring an additional 1,058,331 shares during the period. Geode Capital Management LLC lifted its stake in shares of Gilead Sciences by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after purchasing an additional 749,047 shares during the period. Norges Bank acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at about $1,789,254,000. Finally, Invesco Ltd. grew its position in shares of Gilead Sciences by 12.9% during the 4th quarter. Invesco Ltd. now owns 11,277,915 shares of the biopharmaceutical company's stock valued at $1,041,741,000 after acquiring an additional 1,292,399 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the transaction, the chief financial officer now owns 168,174 shares of the company's stock, valued at $17,893,713.60. The trade was a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 302,785 shares of company stock valued at $30,540,875 over the last quarter. Company insiders own 0.27% of the company's stock.

Gilead Sciences Stock Up 2.2 %

Shares of Gilead Sciences stock traded up $2.33 during trading hours on Wednesday, reaching $106.54. 9,624,028 shares of the company were exchanged, compared to its average volume of 7,522,666. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The stock's fifty day moving average is $109.07 and its 200 day moving average is $98.52. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market cap of $132.66 billion, a PE ratio of 287.95, a PEG ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the previous year, the business earned ($1.32) EPS. Gilead Sciences's revenue for the quarter was down .3% on a year-over-year basis. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.97%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Analyst Ratings Changes

GILD has been the topic of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Piper Sandler lifted their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Oppenheimer lowered their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Cantor Fitzgerald began coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. Finally, The Goldman Sachs Group boosted their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $109.43.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.